The Nigerian antihypertensive adherence trial: A community-based randomized trial

Journal of Hypertension

Volumn 31, Issue 1, 2013, Pages 201-207

  Adeyemo, Adebowale ^a,d,e   Tayo, Bamidele O ^b   Luke, Amy ^b   Ogedegbe, Olugbenga ^c   Durazo Arvizu, Ramon ^b   Cooper, Richard S ^b  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF IBADAN   (Nigeria)

^e HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

adherence; antihypertensive; compliance trial; randomized trial

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; RIBOFLAVIN;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL PROTOCOL; COMMUNITY CARE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; NIGERIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; RURAL AREA; TREATMENT OUTCOME; URBAN AREA;

EID: 84871714312     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32835b0842     Document Type: Article

References (24)

1. Edwards R, Unwin N, Mugusi F, Whiting D, Rashid S, Kissima J, et al. Hypertension prevalence and care in an urban and rural area of Tanzania. J Hypertens 2000; 18:145-152.
2. Fuentes R, Ilmaniemi N, Laurikainen E, Tuomilehto J, Nissinen A. Hypertension in developing economies: a review of population-based studies carried out from 1980 to 1998. J Hypertens 2000; 18:521-529.
3. Pobee JO. Community-based high blood pressure programs in sub-Saharan Africa. Ethn Dis 1993; 3 (Suppl):S38-S45.
4. Walker RW, McLarty DG, Kitange HM, Whiting D, Masuki G, Mtasiwa DM, et al. Stroke mortality in urban and rural Tanzania. Adult Morbidity and Mortality Project. Lancet 2000; 355:1684-1687.
5. Arroyo P, Fernandez V, Loria A, Kuri-Morales P, Orozco-Rivadeneyra S, Olaiz G, et al. Hypertension in urban Mexico: the 1992-93 national survey of chronic diseases. J Hum Hypertens 1999; 13:671-675.
6. Erdine S. How well is hypertension controlled in Europe? J Hypertens 2000; 18:1348-1349.
7. Karppanen H, Mervaala E. Adherence to and population impact of nonpharmacological and pharmacological antihypertensive therapy. J Hum Hypertens 1996; 10 (Suppl 1):S57-S61.
8. Kaufman JS, Rotimi CN, Brieger WR, Oladokum MA, Kadiri S, Osotimehin BO, et al. The mortality risk associated with hypertension: preliminary results of a prospective study in rural Nigeria. J Hum Hypertens 1996; 10:461-464.
9. Klungel OH, de Boer A, Paes AH, Seidell JC, Nagelkerke NJ, Bakker A. Undertreatment of hypertension in a population-based study in The Netherlands. J Hypertens 1998; 16:1371-1378.
10. Reddy KS. Hypertension control in developing countries: generic issues. J Hum Hypertens 1996; 10 (Suppl 1):S33-S38.
11. Cooper R, Puras A, Tracy J, Kaufman J, Asuzu M, Ordunez P, et al. Evaluation of an electronic blood pressure device for epidemiological studies. Blood Press Monit 1997; 2:35-40.
12. Dubbert PM, King A, Rapp SR, Brief D, Martin JE, Lake M. Riboflavin as a tracer of medication compliance. J Behav Med 1985; 8:287-299.
13. Hungerbuhler P, Bovet P, Shamlaye C, Burnand B, Waeber B. Compliance with medication among outpatients with uncontrolled hypertension in the Seychelles. Bull World Health Organ 1995; 73:437-442.
14. Kapur S, Ganguli R, Ulrich R, Raghu U. Use of random-sequence riboflavin as a marker of medication compliance in chronic schizophrenics. Schizophr Res 1991; 6:49-53.
15. Fawzi WW, Msamanga GI, Spiegelman D, Urassa EJ, Hunter DJ. Rationale and design of the Tanzania Vitamin and HIV Infection Trial. Control Clin Trials 1999; 20:75-90.
16. Schaid DJ, Ingle JN, Wieand S, Ahmann DL. A design for phase II testing of anticancer agents within a phase III clinical trial. Control Clin Trials 1988; 9:107-118.
17. Degli Esposti L, Saragoni S, Batacchi P, Benemei S, Geppetti P, Sturani A, et al. Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: results from an administrative database analysis. Clin Ther 2012; 34:190-199.
18. Corrao G, Zambon A, Parodi A, Poluzzi E, Baldi I, Merlino L, et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens 2008; 26:819-824.
19. Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. CMAJ 1999; 160:31-37.
20. Saunders LD, Ntoane C, Wilson TD. Why don't patients return for antihypertensive treatment in Soweto? S Afr Med J 1983; 64:208-210.
21. Mendis S, Johnston SC, Fan W, Oladapo O, Cameron A, Faramawi MF. Cardiovascular risk management and its impact on hypertension control in primary care in low-resource settings: a cluster-randomized trial. Bull World Health Organ 2010; 88:412-419.
22. Cooper RS, Osotimehin B, Kaufman JS, Forrester T. Disease burden in sub-Saharan Africa: what should we conclude in the absence of data? Lancet 1998; 351:208-210.
23. Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 1997; 102 (2A):43-49.
24. Cooper RS, Muna W, Kingue S, Osotimehin B, Kadiri S, Rotimi C, et al. The burden of hypertension in rural Africa: results from the international collaborative study on hypertension in Blacks (ICSHIB). Trop Cardiol 1996; 22:69-75.